Abstract Aims Accumulation of advanced glycation endpoints is a trigger to the development of diabetic peripheral neuropathy, which is a common complication of diabetes. Oral administration of benfotiamine (BFT) has shown some preclinical and clinical promise as a treatment for diabetic peripheral neuropathy. The purpose of this study was to evaluate the method of transdermal delivery of BFT as a possible, viable route of administration for the treatment of diabetic peripheral neuropathy.
Methods A single application of 10 mg of BFT was given to guinea pigs topically. The levels of thiamine (T), thiamine monophosphate, thiamine diphosphate, S-benzoylthiamine and BFT were measured in the blood, skin and muscle at different time points within 24 h.
Results At the 24-h time point, following the single BFT dose, the T level was increased 109 in the blood, more than 79 in the skin and almost 49 in the muscle compared to the untreated animals. The total T content (total) was increased 79 in the blood, 179 in the skin and 39 in the muscle compared to the untreated animals.
Conclusions This strong increase in the tissue levels of T and the associated metabolic derivatives levels found in the blood and local tissues following a single dose indicate that topically applied BFT may be a viable and advantageous
Methods A single application of 10 mg of BFT was given to guinea pigs topically. The levels of thiamine (T), thiamine monophosphate, thiamine diphosphate, S-benzoylthiamine and BFT were measured in the blood, skin and muscle at different time points within 24 h.
Results At the 24-h time point, following the single BFT dose, the T level was increased 109 in the blood, more than 79 in the skin and almost 49 in the muscle compared to the untreated animals. The total T content (total) was increased 79 in the blood, 179 in the skin and 39 in the muscle compared to the untreated animals.
Conclusions This strong increase in the tissue levels of T and the associated metabolic derivatives levels found in the blood and local tissues following a single dose indicate that topically applied BFT may be a viable and advantageous
Attachments
Last edited: